US Targets Foreign Drug Imports in National Security Move
President Donald Trump escalated trade tensions this week by imposing 100% tariffs on select patented pharmaceuticals and ingredients, citing national security concerns. The measure, effective July 31, 2026, exempts generic drugs and advanced therapies while creating tiered rates for allied nations.
Three-Tiered Tariff Structure
Under Thursday's executive order, most imports face full tariffs unless manufacturers establish US production plans approved by the Commerce Secretary – which would temporarily lower rates to 20%. This relief expires April 2, 2030. Close trade partners like the Republic of Korea and Japan face 15% duties, while UK imports attract 10% rates.
Market Implications
The exemption for biosimilars and gene therapies suggests strategic protection of emerging medical technologies. Analysts predict this could accelerate pharmaceutical reshoring trends first seen during the 2020s supply chain reforms. Asian manufacturers supplying patented drugs to US markets face immediate strategic reviews.
